Pub Date : 2026-03-01Epub Date: 2026-03-14DOI: 10.1016/j.clon.2025.104025
Qurrat-ul-ain Tahir, Henry Brice, Anita Nagetey
{"title":"Real world safety and toxicity profile of Pembrolizumab in Neoadjuvant setting in comparison to KEYNOTE-522","authors":"Qurrat-ul-ain Tahir, Henry Brice, Anita Nagetey","doi":"10.1016/j.clon.2025.104025","DOIUrl":"10.1016/j.clon.2025.104025","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104025"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-01-07DOI: 10.1016/j.clon.2026.104031
J.M. Callueng , M. Liu , B. Mou
{"title":"Authors’ Response to Re-evaluating the 30 Gy Dose for Chest Wall-Abutting Tumours in Single-Fraction Stereotactic Ablative Radiotherapy: Evidence From a Population-Based Study","authors":"J.M. Callueng , M. Liu , B. Mou","doi":"10.1016/j.clon.2026.104031","DOIUrl":"10.1016/j.clon.2026.104031","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104031"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146046279","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-14DOI: 10.1016/j.clon.2025.104023
Pavetha Seeva, Nicky Levitt, Helen Turner, Ramnik Buttar
{"title":"Assessing if a Random Cortisol is sufficient to guide surgical safety in TNBC treated with Neoadjuvant Immunotherapy: The Oxford experience","authors":"Pavetha Seeva, Nicky Levitt, Helen Turner, Ramnik Buttar","doi":"10.1016/j.clon.2025.104023","DOIUrl":"10.1016/j.clon.2025.104023","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104023"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-14DOI: 10.1016/j.clon.2025.104015
Eliza Gimson, Juliet Richman, Neha Chopra, Amna Sheri, Jackie Newby, Judy King
{"title":"Readiness for adjuvant ribociclib – results of a local audit and national survey","authors":"Eliza Gimson, Juliet Richman, Neha Chopra, Amna Sheri, Jackie Newby, Judy King","doi":"10.1016/j.clon.2025.104015","DOIUrl":"10.1016/j.clon.2025.104015","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104015"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448866","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-14DOI: 10.1016/j.clon.2025.104026
Ismini Tsagkaraki, Anil Babar, Madhumita Bhattacharyya
{"title":"Neoadjuvant chemotherapy plus pembrolizumab vs chemotherapy alone for patients with early and advanced triple-negative breast cancer (TNBC): Outcomes from Berkshire Cancer Centre","authors":"Ismini Tsagkaraki, Anil Babar, Madhumita Bhattacharyya","doi":"10.1016/j.clon.2025.104026","DOIUrl":"10.1016/j.clon.2025.104026","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104026"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-03-01Epub Date: 2026-03-14DOI: 10.1016/j.clon.2025.104011
Myrto Kastrisiou , Susanna Slater , Mae Alghawas , Diego Himenez , Stephen Johnston (Professor) , Emma Kipps , Marina Parton , Nicholas Turner (Professor) , Alicia Okines
{"title":"Clinical features and outcomes of triple-negative apocrine carcinomas of the breast: A tertiary centre experience over 20 years","authors":"Myrto Kastrisiou , Susanna Slater , Mae Alghawas , Diego Himenez , Stephen Johnston (Professor) , Emma Kipps , Marina Parton , Nicholas Turner (Professor) , Alicia Okines","doi":"10.1016/j.clon.2025.104011","DOIUrl":"10.1016/j.clon.2025.104011","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"51 ","pages":"Article 104011"},"PeriodicalIF":3.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147448686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-06DOI: 10.1016/j.clon.2026.104074
R L Westley, L A Daamen, F R Teunissen, D Vesprini, A Choudhury, F J Pos, H M Verkooijen, C D Fuller, S Choi, W A Hall, J R N van der Voort van Zyp, J P Christodouleas, A C Tree
Aims: Prostate stereotactic body radiotherapy (SBRT) can be delivered using magnetic resonance imaging-guided radiotherapy (MRgRT) with the aim of increased precision and reduced toxicity. The overall treatment time (OTT) for SBRT varies, ranging from daily fractions to once-weekly schedules. However, it is unclear whether OTT affects clinical outcomes when using MRgRT. The aim of this study was to establish whether OTT impacts toxicity, quality of life (QoL), and prostate-specific antigen (PSA) control in prostate MRgRT.
Materials and methods: For this study, outcomes from the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac (MOMENTUM) study were utilised (NCT04075305). Patients with localised prostate cancer receiving 36.25 Gy to 40 Gy in five fractions, of whom OTT was available, were analysed. Physician-reported Common Terminology Criteria for Adverse Event (CTCAE) toxicity, patient-reported outcomes (PROs) and PSA dynamics were collected at baseline and at three, six, twelve, and 24 months after MRgRT. Univariate ordinal logistic regression and mixed model analysis were performed to study the impact of OTT on changes in genitourinary (GU) and gastrointestinal (GI) toxicity, and QoL and PSA levels compared to baseline, respectively.
Results: A total of 858 patients were included with a median OTT of 14 days, ranging from five to 47 days. Excluding erectile function, no grade ≥3 GU or GI toxicity was reported. The OTT was not associated with acute or late GU toxicity (odds ratio [OR]: 0.97 [95% confidence interval [CI]: 0.92-1.02]; P = 0.21 and OR 0.99 [95% CI: 0.94-1.05]; P = 0.83) or acute and late GI toxicity (OR 0.89 [95% CI: 0.79-1.00]; P = 0.05 and OR 0.99 [95% CI: 0.92-1.07]; P = 0.83). In addition, OTT had no apparent impact on QoL scores and PSA kinetics.
Conclusion: This study suggests that OTT, generally between 8 and 18 days, in five-fraction MRgRT for prostate cancer does not affect GU and GI toxicity, QoL and PSA control. Clinicians should consider discussing OTT with patients as this will facilitate treating patients to the time frame that suits them best, reducing the impact of treatment on their QoL, whilst also allowing flexibility for busy departments.
目的：前列腺立体定向放射治疗（SBRT）可以通过磁共振成像引导放射治疗（MRgRT）进行，目的是提高精度和降低毒性。SBRT的总体治疗时间（OTT）各不相同，从每日一次到每周一次不等。然而，当使用MRgRT时，OTT是否会影响临床结果尚不清楚。本研究的目的是确定OTT是否影响前列腺MRgRT的毒性、生活质量（QoL）和前列腺特异性抗原（PSA）控制。材料和方法：在本研究中，使用MR-Linac （MOMENTUM）研究放射治疗的多结局评估结果（NCT04075305）。局部前列腺癌患者接受36.25 Gy至40 Gy的五个部分，其中OTT是可用的，分析。在基线和MRgRT后3、6、12和24个月收集医生报告的不良事件通用术语标准（CTCAE）毒性、患者报告的结果（PROs）和PSA动态。采用单变量有序逻辑回归和混合模型分析，分别研究与基线相比，OTT对泌尿生殖系统（GU）和胃肠道（GI）毒性变化以及生活质量和PSA水平的影响。结果：共纳入858例患者，中位生存期为14天，从5天到47天不等。除勃起功能外，未报告≥3级GU或GI毒性。OTT与急性或晚期胃肠道毒性（比值比[or]: 0.97[95%可信区间[CI]: 0.92-1.02]; P = 0.21和or 0.99 [95% CI: 0.94-1.05]; P = 0.83）或急性和晚期胃肠道毒性（or 0.89 [95% CI: 0.79-1.00]; P = 0.05和or 0.99 [95% CI: 0.92-1.07]; P = 0.83）无关。此外，OTT对生活质量评分和PSA动力学无明显影响。结论：本研究提示，在前列腺癌五段式MRgRT治疗中，OTT通常在8 - 18天之间，不影响GU和GI毒性、生活质量和PSA控制。临床医生应该考虑与患者讨论OTT，因为这将有助于在最适合患者的时间框架内治疗患者，减少治疗对其生活质量的影响，同时也为繁忙的部门提供灵活性。
{"title":"Does Overall Treatment Time Impact Toxicity and Clinical Outcomes After Magnetic Resonance Imaging-Guided Stereotactic Body Radiotherapy to the Prostate? An evaluation of the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac Repository.","authors":"R L Westley, L A Daamen, F R Teunissen, D Vesprini, A Choudhury, F J Pos, H M Verkooijen, C D Fuller, S Choi, W A Hall, J R N van der Voort van Zyp, J P Christodouleas, A C Tree","doi":"10.1016/j.clon.2026.104074","DOIUrl":"https://doi.org/10.1016/j.clon.2026.104074","url":null,"abstract":"<p><strong>Aims: </strong>Prostate stereotactic body radiotherapy (SBRT) can be delivered using magnetic resonance imaging-guided radiotherapy (MRgRT) with the aim of increased precision and reduced toxicity. The overall treatment time (OTT) for SBRT varies, ranging from daily fractions to once-weekly schedules. However, it is unclear whether OTT affects clinical outcomes when using MRgRT. The aim of this study was to establish whether OTT impacts toxicity, quality of life (QoL), and prostate-specific antigen (PSA) control in prostate MRgRT.</p><p><strong>Materials and methods: </strong>For this study, outcomes from the Multi-OutcoMe EvaluatioN of radiation Therapy Using the MR-Linac (MOMENTUM) study were utilised (NCT04075305). Patients with localised prostate cancer receiving 36.25 Gy to 40 Gy in five fractions, of whom OTT was available, were analysed. Physician-reported Common Terminology Criteria for Adverse Event (CTCAE) toxicity, patient-reported outcomes (PROs) and PSA dynamics were collected at baseline and at three, six, twelve, and 24 months after MRgRT. Univariate ordinal logistic regression and mixed model analysis were performed to study the impact of OTT on changes in genitourinary (GU) and gastrointestinal (GI) toxicity, and QoL and PSA levels compared to baseline, respectively.</p><p><strong>Results: </strong>A total of 858 patients were included with a median OTT of 14 days, ranging from five to 47 days. Excluding erectile function, no grade ≥3 GU or GI toxicity was reported. The OTT was not associated with acute or late GU toxicity (odds ratio [OR]: 0.97 [95% confidence interval [CI]: 0.92-1.02]; P = 0.21 and OR 0.99 [95% CI: 0.94-1.05]; P = 0.83) or acute and late GI toxicity (OR 0.89 [95% CI: 0.79-1.00]; P = 0.05 and OR 0.99 [95% CI: 0.92-1.07]; P = 0.83). In addition, OTT had no apparent impact on QoL scores and PSA kinetics.</p><p><strong>Conclusion: </strong>This study suggests that OTT, generally between 8 and 18 days, in five-fraction MRgRT for prostate cancer does not affect GU and GI toxicity, QoL and PSA control. Clinicians should consider discussing OTT with patients as this will facilitate treating patients to the time frame that suits them best, reducing the impact of treatment on their QoL, whilst also allowing flexibility for busy departments.</p>","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"53 ","pages":"104074"},"PeriodicalIF":3.0,"publicationDate":"2026-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147466822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-11-20DOI: 10.1016/j.clon.2025.103982
M. Guardascione , L. Foltran , F. Puglisi
{"title":"Chemoradiotherapy for Oesophageal Adenocarcinoma: The Debate is Not Over","authors":"M. Guardascione , L. Foltran , F. Puglisi","doi":"10.1016/j.clon.2025.103982","DOIUrl":"10.1016/j.clon.2025.103982","url":null,"abstract":"","PeriodicalId":10403,"journal":{"name":"Clinical oncology","volume":"50 ","pages":"Article 103982"},"PeriodicalIF":3.0,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145908802","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
扫码关注我们
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号